Please assess the completion status of the following clinical trial:

Trial Title: Sentinel Lymph Node Procedure in Ipsilateral Invasive Breast Cancer Relapse

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients ≥ 18 years old~2. Invasive recurrence (ductal, lobular, other), homolateral breast carcinoma~3. Size of the tumor with ultrasound ≤ 5cm~4. Initial conservative surgery~5. Patient who has already received SLND for her initial cancer, regardless of the SLND result~6. Procedure for the detection of lymph node sentinel by isotopic method +/- colorimetric~7. Minimum delay of one year between the end of radiotherapy for initial breast carcinoma and the treatment / management of ipsilateral recurrence~8. Pregnancy test (urinary or blood) negative for premenopausal patients~9. Information of the patient and obtaining written consent, signed by the patient and the investigator~Exclusion Criteria:~1. Non-invasive recurrence~2. History of ipsilateral axillary dissection~3. History of ipsilateral mastectomy~4. Patient pN + before surgery~5. Metastasis~6. Allergy known to 2 detection products (Blue and radioactive tracer)~7. Pregnant or lactating woman~8. Patient protected or under guardianship or unable to give consent~9. Impossibility of submitting to the medical examination for geographical, social or psychological reasons

- Gender: None
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sentinel LN in breast cancer recurrence (Type: EXPERIMENTAL): Patients with a biopsy assessing an ipsilateral breast tumor recurrence, and a diagnosis of invasive carcinoma after a previous diagnosis of breast cancer that has been treated by breast conservative surgery at least one year before.~Before the SLNB procedure, each patient will have a lymphoscintigraphy to evaluate axillary and extra axillary lymphatic mapping.~Patients will be operated by breast conservative surgery (BCS) or mastectomy. Each patient will have a second SLND followed by a systematic complete ALND.

Based on this trial design, predict the completion outcome and termination type (if applicable).